For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
197 result(s)
phase
3
FINTEPLA® (fenfluramine)
Dravet Syndrome
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome
pre-clinical
ZILBRYSQ® (zilucoplan)
Generalized Myasthenia Gravis
Subcutaneous zilucoplan: evaluation of reproductive toxicology
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension
phase
2
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
pre-clinical
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Evaluation of the effect of rozanolixizumab on pregnancy outcomes and pre- and postnatal development in cynomolgus monkeys
phase
1
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
phase
4/RWE
CIMZIA® (certolizumab pegol)
Rheumatoid Arthritis
Impact of high RF levels on treatment outcomes of certolizumab pegol and adalimumab in RA: a post hoc analysis from the phase 4 EXXELERATE trial
phase
1
CIMZIA® (certolizumab pegol)
Plaque Psoriasis, Crohn's Disease, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases